Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4844769 | 0.93 | KDM4E (0.53) | ALDH1A1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL21577271 | 0.86 | CHRNB2 (0.51) | — | |
| SCHEMBL13986556 | 0.84 | SMN1; SMN2 (0.58) | ALDH1A1KMT2AMAPTLMNARAB9A | |
| SCHEMBL12272227 | 0.84 | KDM4E (0.59) | ALDH1A1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL29976920 | 0.84 | KDM4E (0.59) | ALDH1A1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL7110609 | 0.84 | HSD17B10 (0.52) | ALDH1A1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL29103165 | 0.82 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL15110304 | 0.82 | KMT2A (0.61) | KMT2ARAB9APOLB | |
| SCHEMBL30856532 | 0.82 | KMT2A (0.61) | KMT2ARAB9APOLB | |
| SCHEMBL16673260 | 0.82 | L3MBTL1 (0.52) | ALDH1A1KMT2ALMNARAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746214-A | Novel indoline compounds | FOURNIER LAB SA | 2012-10-24 | — | — | CN | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | ALDH1A1 1819/4885KMT2A 1435/4885MAPT 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.